<DOC>
	<DOC>NCT01185340</DOC>
	<brief_summary>The primary objective of this study is to assess whether LY2216684 12 mg to 18 mg flexible dose once daily is superior to placebo Once Daily in the adjunctive treatment of patients with major depressive disorder (MDD) who are partial responders to their Selective Serotonin Reuptake Inhibitor Treatment (SSRI).</brief_summary>
	<brief_title>A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Women of childbearing potential may participate but must test negative for pregnancy at the time of study entry; both women/men agree to use a reliable method of birth control Are being treated with one of the following SSRIs: escitalopram, citalopram, sertraline, fluoxetine, paroxetine, or fluvoxamine; for at least 6 weeks prior to investigational product dispensing with at least the last 4 weeks at a stable, optimized dose Drug and dosage should be within the labeling guidelines for the specific country Meet criteria for MDD, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text RevisionÂ® (DSMIVTR) criteria Meet criteria for partial response, as defined by investigator's opinion that patient has experienced a minimal clinically meaningful improvement with SSRI Have a GRID 17Item Hamilton Depression Rating Scale (GRIDHAMD17) total score greater than or equal to 16 at screening Have less than or equal to 75% improvement on the current SSRI at screening determined by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGHATRQ) Have had or currently have any additional ongoing DSMIVTR Axis 1 condition other than major depression within 1 year of screening Have had any anxiety disorder that was considered a primary diagnosis within the past year (including panic disorder, obsessivecompulsive disorder [OCD], posttraumatic stress disorder [PTSD], generalized anxiety disorder [GAD], and social phobia, but excluding specific phobias) Have a current or previous diagnosis of a bipolar disorder, schizophrenia, or other psychotic disorder Have a history of substance abuse and/or dependence within the past 1 year (drug categories defined by DSMIVTR), not including caffeine and nicotine Have an Axis II disorder that, in the judgment of the investigator, would interfere with compliance with protocol Unstable medical conditions that contraindicate the use of LY2216684 Have any diagnosed medical condition which could be exacerbated by noradrenergic agents including unstable hypertension, unstable heart disease, tachycardia, tachyarrhythmia, narrowangled glaucoma, history of urinary hesitancy or retention Use of excluded concomitant or psychotropic medication other than SSRI Have initiated or discontinued hormone therapy within the previous 3 months of prior to enrollment History of treatment resistant depression as shown by lack of response of the current depressive episode to 2 or more adequate courses of antidepressant therapy at a clinically appropriate dose for at least 4 weeks, or in the judgment of the investigator, the patient has treatmentresistant depression Have a lifetime history of vagal nerve stimulation (VNS) transcranial magnetic stimulation (TMS), or psychosurgery Have received electroconvulsive therapy (ECT) in the past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>MDD</keyword>
</DOC>